Acute myeloid leukaemia.

Progress in acute myeloid leukaemia treatment is occurring at an unprecedented pace. The past decade has witnessed an increasingly improved scientific understanding of the underlying biology of acute myeloid leukaemia, leading to enhanced prognostication tools and refined risk assessments, and most especially incorporating measurable residual disease (MRD) into longitudinal risk assessments. The classification of acute myeloid leukaemia has recently been updated by WHO and the International Consensus Classification (ICC). Recommendations for prognostic stratification, response assessment, and MRD determination have also been updated by the European LeukemiaNet. Treatment options have evolved substantially in the last 5 years for patients with newly diagnosed acute myeloid leukaemia, leading to improved outcomes in intensively treated patients and those more appropriate for non-intensive chemotherapy. More effective targeted treatment options in the relapsed setting are also available, further advancing the treatment armamentarium and improving patient outcomes.
Competing Interests: Declaration of interests CDD received funding (to institution) from Abbvie, Astex, BMS, Cleave, Foghorn, ImmuneOnc, Loxo, and Servier; received consulting and honorarium fees from Abbvie, BMS, Genmab, Gilead, GSK, Jazz, Kura, Novartis, Servier, and Takeda; and was on the scientific advisory board of Notable Labs. HPE received funding (to institution) from AbbVie, ALX Oncology, Amgen, Ascentage, Daiichi Sankyo, Forma, Gilead, Glycomimetics, Immunogen, Jazz, MacroGenics, Novartis, PTC, and Sumitomo Pharma; received consulting fees from AbbVie, Agios, Astellas, BMS/Celgene, Daiichi Sankyo, Glycomimetics, Immunogen, Incyte, Jazz, Kura Oncology, MacroGenics, Novartis, Pfizer, Servier, Syros, Takeda, Trillium; was on the speaker's bureau for AbbVie, BMS, Incyte, Jazz, Novartis, and Servier. SDF received funding (to institution) from BMS and Jazz; received consulting and honorarium fees from Novartis, and was on the advisory board of Neogenomics and MPAAC. AHW acts on the advisory boards for Novartis, Astra Zeneca, Astellas, Janssen, Amgen, Roche, Pfizer, Abbvie, Servier, Gilead, BMS, Shoreline, Macrogenics and Agios; receives funding (to institution) from Novartis, Abbvie, Servier, Janssen, BMS, Syndax, Astex, Astra Zeneca, and Amgen; serves on the speaker's bureaus for Abbvie, Novartis, BMS, Servier, and Astellas; and is an employee of the Walter and Eliza Hall Institute (WEHI). WEHI receives milestone and royalty payments related to the development of venetoclax. Current and past employees of WEHI may be eligible for financial benefits related to these payments. AHW receives financial benefits from WEHI.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)